MATTHEW ELLIOTT: Open Payments
NPI 1497244792 · PALM SPRINGS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,442 in 74 payments from 14 companies in 2025. Trend: 2023 $172 · 2024 $866 · 2025 $1,442
Food & beverage: $1,442
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 12 | $347 |
| ABBVIE INC. | 20 | $240 |
| Intercept Pharmaceuticals, Inc. | 7 | $146 |
| Janssen Biotech, Inc. | 9 | $143 |
| Ipsen Biopharmaceuticals, Inc | 6 | $134 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Gilead Sciences, Inc. | 4 | $84 |
| Braintree Laboratories, Inc. | 3 | $68 |
| Celltrion USA Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
Products named: REZDIFFRA, OCALIVA, TREMFYA, IQIRVO, DUPIXENT, RINVOQ, SKYRIZI, MAVYRET.
Industry payments across CA — which companies pay providers there.
